Skip to main content
. 2017 Feb 9;12(2):e0172024. doi: 10.1371/journal.pone.0172024

Table 2. Fold change ratios in the gene expression of septic patients compared to the healthy volunteers at admission and after seven days of follow-up, according to the outcomes.

D0 D7
Gene All (N = 16) S (N = 8) NS(N = 8) All (N = 10)
TLR4 1.08 -1.06 1.25 1.05
CD14 1.17 1.05 1.34 -1.11
LY96 1.1 1.02 1.24 -1.12
MYD88 1.1 -1.06 1.25 -1.01
IRAK3 1.41 1.21 1.64 a 1.3
TRAF6 -1.81 a -1.70 a -2.14 a -1.47
ECSIT -1.3 -1.31 -1.35 -1.23
IRF5 -1.22 -1.08 -1.35 -1.11
CHUK -1.04 -1.21 1.01 -1.1
IKBKG -1.12 -1.09 -1.14 1.09
NFKBIA 1.22 -1.21 1.62 1.35
NFKB1 1.09 1.17 1.08 -1.16
RELA (p65) -1.41 -1.38 -1.45 -1.34
MAPK7 (ERK) -1.86 a -1.69 a -2.14 a -1.66 a
MAP2K3 (MKK3) 1.29 1.2 1.52 a 1.05
MAPK14 1.24 1.21 1.32 1.25
MAP2K7 (MKK7) -1.49 -1.39 -1.66 a -1.25
MAPK8 (JNK1) -1.74 a -1.69 a -1.85 a -1.41
JUN (AP1) -2.05 a -1.70 -2.78 a -1.43
TICAM1 -1.11 -1.33 1 -1.17
IRF7 -1.54 a -1.73 a -1.50 -1.35
IRF3 -1.61 a -1.58 -1.70 a -1.37
IFNAR1 -1.23 -1.08 -1.51 a -1.27
IFNAR2 -1.2 -1.12 -1.39 -1.53
JAK1 -1.80 a -1.68 a -2.22 a -1.64
TYK2 -1.37 -1.31 -1.47 -1.29
STAT1 -1.78 a -2.46 a -1.80 -1.13
STAT2 -1.58 a -1.72 -1.77 a -1.36
IRF9 -1.52 a -1.66 a -1.61 a -1.19
IFNGR1 (IFNGR) 1.04 1.13 1.04 1.11
IFNGR2 (AF-1) 1.46 1.4 1.60 a 1.23
JAK2 -1.48 -1.69 -1.57 -1.17
SOCS3 -1.07 -1.02 -1.22 -1.23
IRF1 -1.94 a -2.37 a -2.17 a -1.36
NOS1 1 -1.35 1.46 -1.4
NOS2 -1.09 -1.02 -1.12 -1.34
NOS3 -2.54 -1.91 -3.52 a -1.85
SOD1 -1.6 -1.4 -2.02 a -1.56 a
SOD2 2.15 a 1.37 3.45 a 2.12 a
SOD3 -1.35 -1.59 1.03 -1.12
CYBB (gp91) -1.1 -1.35 1.11 -1.1
NCF1 (p47phox) 1.15 -1.06 1.52 1.56
RAC1 -1.03 -1.05 -1.12 -1.04
UCP2 -1.31 -1.42 -1.38 -1.1
GPX1 1.34 1.41 1.46 1.58 a
PRDX3 -1.07 -1.02 -1.27 -1.17
PRDX4 -1.04 1.13 -1.35 1
CAT 1 -1.02 -1.03 -1.15
TXN 1.11 1.1 1.17 1.03
TXNRD1 -1.12 -1.11 -1.22 -1.07
TXNRD2 -1.22 -1.22 -1.26 -1.21
NDUFA4 -1.41 -1.37 -1.55 a -1.31
NDUFA5 -1.41 -1.06 -1.86 a -1.22
NDUFA7 -1.35 -1.34 -1.54 a -1.26
NDUFA8 -1.18 -1.17 -1.28 -1.11
NDUFA9 -1.38 -1.37 -1.49 -1.21
NDUFA10 -1.39 -1.28 -1.57 a -1.28
NDUFA11 -1.19 -1.15 -1.16 -1.21
NDUFB5 -1.45 -1.35 -1.73 a -1.33
NDUFB6 -1.37 -1.31 -1.58 a -1.22
NDUFC2 -1.90 a -1.77 -2.31 a -1.58 a
COX4I2 -1.83 a -1.91 -1.62 -1.39
COX5A -1.15 -1.02 -1.36 -1.16
COX5B -1.29 -1.33 -1.28 -1.19
COX6A2 1.18 -1.01 1.31 -1.26
COX7A2 -1.29 -1.12 -1.59 a -1.36
COX7C -1.49 -1.4 -1.67 a -1.34
COX10 -1.66 a -1.65 -1.74 a -1.30
ATP5B -1.2 -1.16 -1.27 -1.17
ATP5C1 -1.32 -1.22 -1.56 a -1.28
ATP5F1 -1.4 -1.26 -1.76 a -1.34
ATP5J -1.18 -1.12 -1.33 -1.18
ATP6V1C1 1.22 1.24 1.12 1.04
ATP6V1E1 -1.17 -1.13 -1.23 -1
ATP6V1E2 -1.56 -1.28 -1.97 a -1.51 a
UQCRC2 -1.41 -1.46 -1.43 -1.29
TNF 1.04 -1.99 1.54 1.3
IL1B 1.38 -2.24 2.9 1.56
IFNA1 -1.04 -1.05 1.18 -1.16
IFNB1 1.12 -1.49 1.67 1.58
IL10 1.96 2.87 a 1.73 1.22
IL6 3.6 1.08 7.42 2.23
CXCL10 -2.49 -5.16 -2.02 -1.49
IL12A -1.5 -1.28 -2.29 a -1.22

Footnote: D0 represents total septic patients after admission and D7 represents samples obtained after 7 days. S: survivors and NS: non-survivors. The bold letters show fold change ≥1.5 and the letter “a” indicates P value ≤0.05.